Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events in patients with diabetes and overt nephropathy: a meta-analysis of randomised controlled trials

Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials

(2016) Xinfang Xie et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

(2016) Vlado Perkovic et al.   KIDNEY INTERNATIONAL

Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis

(2015) Suetonia C Palmer et al.   LANCET

Commentary on the KDIGO Clinical Practice Guideline for the management of blood pressure in chronic kidney disease

(2013) Matthew A Roberts   NEPHROLOGY

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis

(2012) Caroline S Fox et al.   LANCET

Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study

(2012) Marcello Tonelli et al.   LANCET

Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study

(2011) E. Imai et al.   DIABETOLOGIA

Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials

(2011) A. Maione et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Avosentan for Overt Diabetic Nephropathy

(2010) J. F.E. Mann et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY